Lenalidomide-induced interstitial lung disease.


Lenalidomide is a more potent and less toxic oral analog of thalidomide. The drug is indicated for treatment of multiple myeloma and other hematologic disorders and has rarely been associated with pulmonary toxicity. We describe a 73-year-old woman who received lenalidomide therapy for multiple myeloma. Nine weeks after starting the drug, she developed… (More)
DOI: 10.1592/phco.30.3.325


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics